Transgene will present its therapeutic vaccines to investors on October 6
Strasbourg-based biotech company Transgene announced on October 1, 2026 that its management team will meet with institutional investors at an event organized in Paris. This will be an opportunity for the company to present the progress of candidates from its personalized therapeutic vaccine platform.
A meeting with institutional investors on October 6
Transgene announced that its management team will participate in the next edition of the Investor Access Event, organized by Investor Access, on October 6, 2026 in Paris. These events bring together listed companies with institutional investors through targeted meetings with management teams.
According to the company, the 2026 program brings together more than 190 professional investors and 90 listed companies across all of its events.
Myvac platform candidates at the heart of the presentation
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
During this event, Transgene will present advances in candidates from its Myvac platform, namely TG4050 in head and neck cancer and TG4070 in non-small cell lung cancer, as well as other programs based on viral vectors.
TG4050 is described by the company as its flagship candidate and the first personalized treatment derived from the Myvac platform, having demonstrated clinical proof of concept in patients with head and neck cancer treated in the adjuvant setting. TG4070 is in phase 1 of clinical development in the adjuvant setting in patients with non-small cell lung cancer.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 0,3 millions d'euros
Quarterly revenue: 0,3 millions d'euros
Net income: -15,7 millions d'euros
Guidance from the release
« Based on the above elements, Transgene estimates that it will be financed until early 2028. » ; « expects to communicate topline results from TG4050's Phase 1/2 trial by the end of Q1 2028 »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
